Effects of Hypothyroidism Treatment on the Level of Vascular Endothelial Growth Factor
Journal Title: Міжнародний ендокринологічний журнал - Year 2015, Vol 6, Issue 70
Abstract
The objective of the investigation is identifying the level of vascular endothelial growth factor in patients with primary hypothyroidism and influence of complex treatment on its levels. Materials and methods. One hundred and thirty three patients with primary hypothyroidism were examined. All patients were grouped into group 1 containing 32 patients with hypothyroidism resulted from autoimmune thyroiditis (AIT) without obesity; group 2 involving 34 obese patients with autoimmune thyroiditis and hypothyroidism; group 3 including 34 patients with manifested hypothyroidism without obesity and Group 4, encompassing the rest 33 obese patients with post-operative hypothyroidism. Results. Patients’ data have shown significant increase of vascular endothelial growth factor levels in all groups, but the most expressed changes of vascular endothelial growth factor secretion have been noticed in obese patients with hypothyroidism resulting from autoimmune thyroidism. The possibility to increase the efficacy of treating such patients by means of complex use of LT4, enalapril and atorvastatin for six months has been discussed. Such complex use of LT4, enalapril and atorvastatin enhances the therapeutic effect of the background therapy and decreases the overproduction of vascular endothelial growth factor. Conclusions. With manifested hypothyroidism, levels of vascular endothelial growth factor in blood plasma are significantly higher in both obese and not obese patients. The highest indices have been found in obese patients with manifested hypothyroidism resulting from autoimmune thyroidism. Complex use of LT4, enalapril and atorvastatin for six months decreases vascular endothelial growth factor overproduction.
Authors and Affiliations
O. M. Didushko
Keywords
Related Articles
- EP ID EP219430
- DOI -
- Views 67
- Downloads 0
Endocrine Ophthalmopathy in Autoimmune Thyroid Diseases
The article presents modern data about risk factors, mechanisms of development, clinical features of endocrine ophthalmopathy, as well as information regarding current approaches to diagnosis, treatment and prevention of...
Amaryl®М SR: a New Release Form, New Possibilities for The Patients
The review deals with a new form of oral antidiabetic drugs with a fixed dose — the combination of sustained-release metformin and glimepiride. Amaryl®M SR (2/500 mg) — a new dosage form, which provides a rapid release o...
ORIGIN Trial (Background, Results)
ORIGIN — the longest and most extensive study on Lantus® use in patients with cardiovascular risk with diabetes mellitus (DM) type 2 in the early stages, as well as prediabetes, in which insulin therapy is not indicated...
Clinical Approaches to the Treatment of Diabetic Neuropathy
The article is devoted to the treatment of diabetic neuropathy. The described scheme of application of preparations of alpha-lipoic (thioctic) acid. Recently in Europe and the United States conducted a series of clinical...
Features of Immune and Metabolic Changes in patients with Combined Endocrine Pathology and Vitamin D3 Deficiency
Aim. To study the cytokines background concentration in patients with combined endocrine pathology — diabetes mellitus (DM) type 1 or 2 and autoimmune thyroiditis secondary to vitamin D3 deficiency. Methods. The examined...